Da-6886

Da-6886

SCHEMBL725324

COc1cc(N)c(Cl)cc1C(=O)NCC1CCN(CCCn2ccnn2)CC1.Cl

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Da-6886. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTR4 known ✓ Q13639 16/20 0.98
DRD2 known ✓ P14416 2/20 0.57
DRD4 known ✓ P21917 2/20 0.57
DRD3 known ✓ P35462 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Da-6886 SCHEMBL726214 0.99 HTR4 (1.00) HTR4DRD2DRD4DRD3
Hydrochloric Acid SCHEMBL725813 0.98 HTR4 (0.98) HTR4DRD2DRD4DRD3
SCHEMBL724283 0.97 HTR4 (1.00) HTR4DRD2DRD4DRD3
SCHEMBL725841 0.94 HTR4 (0.94) HTR4DRD2DRD4DRD3
SCHEMBL23838507 0.91 HTR4 (0.84) HTR4DRD2DRD4DRD3
Hydrochloric Acid SCHEMBL725773 0.89 HTR4 (0.98) HTR4DRD2DRD4DRD3
SCHEMBL727020 0.88 HTR4 (1.00) HTR4DRD2DRD4DRD3
SCHEMBL17787934 0.87 HTR4 (0.79) HTR4DRD2DRD4DRD3
SCHEMBL725807 0.85 HTR4 (1.00) HTR4DRD2DRD4DRD3
SCHEMBL19387655 0.85 HTR4 (0.75) HTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560955-B1 NOVEL BENZAMIDE DERIVATIVES DONG A PHARM CO LTD (KR) 2016-06-29 EP claimed
US-9221790-B2 Benzamide derivatives DONG-A PHARM. CO., LTD. (KR) 2015-12-29 US claimed
US-20130085160-A1 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM. CO., LTD. (KR) 2013-04-04 US claimed
EP-2560955-A2 NOVEL BENZAMIDE DERIVATIVES Dong-A Pharm.Co., Ltd. (KR) 2013-02-27 EP claimed
WO-2011132901-A2 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM.CO., LTD. (KR) 2011-10-27 WO claimed
US-20210338647-A1 Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-11-04 US disclosed
EP-3026049-B1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE DONG A ST CO LTD (KR) 2021-09-22 EP disclosed
EP-3628315-A1 COMBINATION OF ACETYLCHOLINESTERASE INHIBITOR AND 5-HT4 RECEPTOR AGONIST AS NEUROPROTECTIVE AGENT IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Université de Caen Normandie (FR) 2020-04-01 EP disclosed
US-9771348-B2 Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate DONG-A ST CO., LTD (KR) 2017-09-26 US disclosed
US-20160185751-A1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE DONG-A ST CO., LTD (KR) 2016-06-30 US disclosed
EP-2560955-B1 NOVEL BENZAMIDE DERIVATIVES DONG A PHARM CO LTD (KR) 2016-06-29 EP disclosed
EP-3026049-A1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE Dong-A ST Co., Ltd. (KR) 2016-06-01 EP disclosed
US-9221790-B2 Benzamide derivatives DONG-A PHARM. CO., LTD. (KR) 2015-12-29 US disclosed
US-20130085160-A1 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM. CO., LTD. (KR) 2013-04-04 US disclosed
EP-2560955-A2 NOVEL BENZAMIDE DERIVATIVES Dong-A Pharm.Co., Ltd. (KR) 2013-02-27 EP disclosed
WO-2011132901-A2 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM.CO., LTD. (KR) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338647-A1 Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases HTR4, ACHE, CHRNA4 HTR4 1/4885DRD2 162/4885DRD4 114/4885
US-20160185751-A1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE HTR4, HTR5A, HTR2B HTR4 1/4885DRD2 75/4885DRD4 30/4885
US-20130085160-A1 NOVEL BENZAMIDE DERIVATIVES HTR4, GPR4, HTR5A HTR4 1/4885DRD2 570/4885DRD4 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.